TITLE

VITAL SCIENTIFIC MAY ARBITRATE WITH SCIL DIAGNOSTICES

PUB. DATE
August 2000
SOURCE
Worldwide Biotech;Aug2000, Vol. 12 Issue 8, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the dispute between Vital Scientific NV and Scil Diagnostics GmbH over agreements to develop and manufacture Scil, a clinical chemistry instrument.
ACCESSION #
3449621

 

Related Articles

  • Scil Technology to Bank $239M+ In Osteoarthritis Deal with Sanofi. Moran, Nuala // BioWorld International;12/21/2011, Vol. 16 Issue 51, p1 

    The article reports on a deal entered into by Scil Technology GmbH with Sanofi as its commercial partner for its protein therapy for osteoarthritis. According to Christian Nafe, chief executive officer (CEO) of Scil Technology, it will take 10 years to trigger all the milestone payments. Human...

  • Scil Proteins Successfully Completes Manufacture of Recombinant Protein Candidate for Lundbeck.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p836 

    The article reports on the announcement by biopharmaceutical company Scil Proteins GmbH in Halle, Germany that they have successfully completed a manufacturing deal with global pharmaceutical company Lundbeck A/S for a recombinant protein candidate. Scil Proteins chief executive officer (CEO)...

  • Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug. Sheridan, Cormac // BioWorld International;1/23/2008, Vol. 13 Issue 4, p1 

    The article reports on the decision of Scil Technology GmbH and Pfizer Inc. to enter into a $250 million deal for the development of a preclinical osteoarthritis drug. Under the agreement, Scil Technology would receive royalties on product sales. The company will be out-licensing rights to...

  • Staying Positive in the Gloom; European Biotechs Muddle Through Despite Lack of VC. Sheridan, Cormac // BioWorld International;11/9/2011, Vol. 16 Issue 45, p2 

    The article discusses the highlights of BIO-Europe Fall 2011 in Dusseldorf, Germany. Noted is the importance of optimism to the biotechnology in Europe, which is facing early stage venture capital (VC) investment issues. Frank Rathgeb of Sygnis Pharma AG and Hank Loy of Inflammagen Therapeutics...

  • Staying Positive in the Gloom; European Biotechs Muddle Through Despite Lack of VC. Sheridan, Cormac // BioWorld Today;11/3/2011, Vol. 22 Issue 214, p1 

    The article examines prospects for the European biotechnology industry amid a lack of venture capital (VC) in the region. It notes the funding gap facing German companies that prevent innovations from reaching the clinic. It also notes the reluctance of pharmaceutical companies to enter early...

  • Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug. Sheridan, Cormac // BioWorld Today;1/17/2008, Vol. 19 Issue 12, p1 

    The article reports on the license deal signed between Scil Technology GmbH and Pfizer Inc. The deal involved the out-licensing of rights to cartilage-derived retinoic acid sensitive protein (CD-RAP), a growth factor expressed in cartilage tissue. CD-Rap is an 11-kilo Dalton secreted protein...

  • WEEK IN REVIEW.  // BioWorld Insight;12/27/2011, Vol. 19 Issue 52, p5 

    The article offers news briefs related to pharmaceutical biotechnology industry in the U.S. It notes that Excelimmune Inc. has generated 12 million dollars from a private investor to support its infectious research. It adds that a 235.9 million dollars osteoarthritis deal has been finalized...

  • BioNet Holding Banks on Scil Proteins with $33M Financing. Powers, Marie // BioWorld International;2/9/2011, Vol. 16 Issue 6, p3 

    The article reports on the financing round concluded by Scil Proteins GmbH with BioNet Holding GmbH. The proceeds will be used for preclinical products derives from Scil's Affilin scaffold technology platform. According to Scil chief financial officer Frank Ubags, the financing has made a...

  • BioNet Holding Banks on Scil Proteins with $33M Financing. Powers, Marie // BioWorld Today;2/3/2011, Vol. 22 Issue 23, p1 

    The article reports that 24 million euros have been invested by BioNet Holding GmbH in Scil Proteins GmbH in a financing round. Proceeds will be used to fund Phase 1 studies of two products in the Affilin scaffold technology platform of Scil. Company chief financial officer (CFO) Frank Ubags...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics